AOD9604

AOD9604 is the peptide researchers reach for when they want the fat-metabolizing signal of human growth hormone without its growth-promoting or diabetogenic baggage. This synthetic 16-amino-acid fragment reproduces hGH’s lipolytic domain and nothing else. In obese animal models, daily dosing cut body-weight gain by more than half while leaving insulin sensitivity untouched.¹ If your protocol calls for high-purity, lab-tested Canadian peptides, Helixx supplies research-grade AOD9604 Canada-wide for laboratory and educational use only.

What Is AOD9604?

AOD9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to the C-terminal lipolytic domain of human growth hormone (specifically hGH residues 177-191, with an added N-terminal tyrosine), assembled as a 16-amino-acid (hexadecapeptide) chain. The idea is straightforward: isolate the region of the growth-hormone molecule responsible for fat breakdown, and leave behind the domains that drive tissue growth and interfere with carbohydrate metabolism. The result is a compound that mimics hGH’s effect on adipose tissue while, in studies to date, showing none of hGH’s characteristic rise in serum IGF-1 and no impairment of glucose tolerance. It has become a widely referenced subject in metabolic and obesity research, and more recently in cartilage and joint-repair investigation. As with all products supplied by Helixx, AOD9604 is intended for laboratory, research and educational use only and is not for human consumption.

How AOD9604 Works

AOD9604 stimulates lipolysis (the breakdown of stored triglycerides into glycerol and free fatty acids) while simultaneously inhibiting lipogenesis, the formation of new fat. In obese Zucker rats, daily oral AOD9604 increased lipolytic activity and reduced lipogenic activity in adipose tissue, producing a marked reduction in body-weight gain without adverse effects on insulin sensitivity.¹ The peptide appears to upregulate repressed beta-3 adrenergic receptor (beta3-AR) expression in the adipose tissue of obese animals, nudging it back toward lean-animal levels and enhancing lipolytic sensitivity. That beta3-AR pathway is associated with its activity, though not solely responsible for it: in beta3-AR knockout mice, chronic weight-loss effects were absent, yet AOD9604 still acutely raised energy expenditure and fat oxidation, pointing to an additional receptor-independent component to its action.² Because it does not engage the growth-hormone receptor in a way that raises IGF-1, AOD9604 separates the metabolic signal from the growth signal, and that separation is what defines the compound.

What the Research Shows

• Core anti-obesity activity. In obese Zucker rats, daily oral AOD9604 (500 ug/kg) for 19 days reduced body-weight gain by over 50% versus controls, increasing lipolytic and reducing lipogenic activity in adipose tissue, and it did so without harming insulin sensitivity.¹
• Mechanism confirmed and clarified. Both hGH and AOD9604 induced weight loss and increased lipolytic sensitivity in obese mice and restored repressed beta3-AR RNA; in beta3-AR knockout mice the chronic effects disappeared, yet acute energy expenditure and fat oxidation still rose, which shows the lipolytic action is linked to, but not fully dependent on, the beta3-AR.²
• Human safety and tolerability. A pooled analysis of six randomized, double-blind, placebo-controlled human trials (893 adults, IV and oral dosing including Phase IIb obesity studies) found AOD9604’s safety profile indistinguishable from placebo: no serious adverse events, no anti-drug antibodies, no rise in serum IGF-1, and no negative effect on oral glucose tolerance.³
• Joint and cartilage application. In a collagenase-induced rabbit knee osteoarthritis model (n=32), ultrasound-guided intra-articular AOD9604 improved gross-morphology and histopathology cartilage scores versus saline, and performed best when combined with hyaluronic acid, which supports a cartilage-regeneration and joint-health line of research.⁴

Researchers frequently study AOD9604 alongside other metabolic and recovery peptides: comparing it with incretin agonists such as Tirzepatide, Retatrutide and Ozempic (Semaglutide), or pairing it with tissue-repair peptides like BPC-157 and TB-500 in joint-focused protocols.

Chemical Properties

Research Protocols & Handling

AOD9604 is supplied strictly for in-vitro and laboratory research and educational purposes. It is not a dietary supplement, not a medicine, and not for human or veterinary use. Lyophilized peptide is typically stored at -20 C for long-term stability and protected from light and moisture; the sealed vial may be kept refrigerated for shorter periods before reconstitution. For research handling, the peptide is generally reconstituted with bacteriostatic or sterile water and, once reconstituted, kept refrigerated and used within a limited window to preserve integrity. Repeated freeze-thaw cycles should be avoided. Handling should follow standard laboratory practice, and the compound should be documented and labelled for research use only. Helixx supplies peptides Canada-wide to qualified researchers; nothing in this listing constitutes dosing guidance for human use.

Potential Side Effects & Safety

References

Peer-reviewed and authoritative sources cited above. Helixx supplies research materials for laboratory and educational use only; citations are provided for independent verification, not as medical guidance.

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11146367.
2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 11713213.
3. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. doi:10.4021/jem157w.
4. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-432. PMID: 26275694.